Theratechnologies (NASDAQ:THTX) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Theratechnologies (NASDAQ:THTX) from a sell rating to a hold rating in a report published on Wednesday, Zacks.com reports.

According to Zacks, “Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It’s main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada. “

Separately, Canaccord Genuity lowered shares of Theratechnologies from a buy rating to a hold rating and lowered their target price for the stock from $8.00 to $3.00 in a report on Thursday, July 29th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Hold and an average price target of $3.17.

THTX opened at $3.61 on Wednesday. The company has a fifty day moving average price of $3.56 and a two-hundred day moving average price of $3.57. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.74 and a current ratio of 2.41. Theratechnologies has a 52 week low of $1.83 and a 52 week high of $4.25. The firm has a market capitalization of $341.92 million, a PE ratio of -12.03 and a beta of 1.65.

Theratechnologies (NASDAQ:THTX) last released its earnings results on Wednesday, July 14th. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). Theratechnologies had a negative net margin of 37.10% and a negative return on equity of 112.84%. The firm had revenue of $17.79 million during the quarter. Equities analysts forecast that Theratechnologies will post -0.19 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in THTX. Commonwealth Equity Services LLC bought a new position in shares of Theratechnologies during the first quarter worth $114,000. MAI Capital Management boosted its position in shares of Theratechnologies by 16.9% during the first quarter. MAI Capital Management now owns 56,023 shares of the company’s stock worth $217,000 after purchasing an additional 8,100 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Theratechnologies by 157.5% during the first quarter. Renaissance Technologies LLC now owns 335,000 shares of the company’s stock worth $1,295,000 after purchasing an additional 204,894 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of Theratechnologies during the first quarter worth $27,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Theratechnologies during the first quarter worth $1,300,000. 19.29% of the stock is currently owned by institutional investors.

About Theratechnologies

Theratechnologies, Inc is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Theratechnologies (THTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.